Response to treatment in pediatric ocular myasthenia gravis

Introduction: Juvenile myasthenia gravis (JMG), a pediatric autoimmune neuromuscular junction disorder, includes generalized (GMG), and ocular (OMG) variants. We sought to determine whether differences existed between OMG and GMG children regarding demographics or treatment response. Methods: We performed retrospective analysis of 60 children with JMG seen between 1990 and 2018. Osserman scores were used to define OMG and GMG. The myasthenia scale of Millichap and Dodge was used to assess treatment responses. Results: There were no differences between GMG and OMG regarding time interval from disease onset to prednisone initiation (P =.42), or treatment response according to Millichap and Dodge (P =.12). Compared with GMG, OMG children showed younger age of disease onset and better outcomes after treatment. No OMG patients progressed to generalized disease during the follow-up period. Discussion: Compared with GMG, OMG patients had earlier disease onset and improved outcomes after treatment.